Shares of the company began plunging in November, but its overall strength should set the stock up for some serious potential ...

Amgen (NASDAQ:AMGN – Get Free Report) is expected to be issuing its quarterly earnings data after the market closes on ...

The Amgen stock price suffered a harsh reversal in the fourth quarter of 2024 as its weight loss drug failed to excite. After peaking at $341 in July, the stock plunged by over 25% to the current ...

Amgen (NASDAQ:AMGN – Free Report) had its price target decreased by Citigroup from $310.00 to $295.00 in a research report released on Tuesday morning,Benzinga reports. Citigroup currently has a ...

In a report released today, Tim Anderson from Bank of America Securities reiterated a Sell rating on Amgen (AMGN – Research Report), with a ...

Today, Benzinga 's options scanner spotted 28 uncommon options trades for Amgen. This isn't normal. The overall sentiment of ...

Shares of Amgen (Nasdaq: AMGN) started crashing in early November and didn’t improve when the company released data from a ...

Amgen's stock price remains nearly unchanged over 1.5 years, but its valuation may now be more reasonable or even a bargain. Despite high debt from the Horizon Therapeutics acquisition ...

On Tuesday, RBC Capital Markets adjusted its price target on Amgen (NASDAQ:AMGN) shares, reducing it to $324 from the previous $330, while maintaining an Outperform rating on the stock.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...